Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | EXEC. VP AND CLO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,272 |
Ending reported balance
After 2026-10-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04 | Direct | 2,267 |
Reported balance
After 2026-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 838 | $65.72 | $55,073.36 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,778 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.26 to $66.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 550 | $64.44 | $35,442.00 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,616 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,265 | $39.42 | $89,286.30 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 906 | $66.63 | $60,366.78 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.42 to $67.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 824 | $65.73 | $54,161.52 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,807 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.26 to $66.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 536 | $64.43 | $34,534.48 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,631 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,266 | $39.42 | $89,325.72 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,500 | $67.15 | $100,725.00 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.00 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,400 | $66.44 | $491,656.00 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,401 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.00 to $66.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,124 | $65.47 | $400,938.28 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,801 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,100 | $64.43 | $199,733.00 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,925 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 18,124 | $39.42 | $714,448.08 |
DisclosureSEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 19 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,751 Underlying: Common Stock · 905 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 18 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,656 Underlying: Common Stock · 1,019 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,661 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 17 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,675 Underlying: Common Stock · 22,661 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 905 | $61.21 | $55,395.05 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 13 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.86 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 905 | $38.10 | $34,480.50 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,019 | $61.31 | $62,474.89 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.83 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,019 | $38.10 | $38,823.90 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 544 | $62.09 | $33,776.96 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.05 to $62.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 22,117 | $61.33 | $1,356,435.61 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,445 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 22,661 | $38.10 | $863,384.10 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,470 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 16 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,336 Underlying: Common Stock · 2,470 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,356 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 15 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,806 Underlying: Common Stock · 2,356 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,838 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · derivative · entry 14 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,162 Underlying: Common Stock · 17,838 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F9 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,470 | $61.00 | $150,670.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,470 | $38.10 | $94,107.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,356 | $61.00 | $143,716.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.02 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,356 | $38.10 | $89,763.60 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 17,838 | $61.00 | $1,088,118.00 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.00 to $61.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 17,838 | $38.10 | $679,627.80 |
DisclosureSEC source: 0001578852-25-000003 · form4-09152025_050901.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,813 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-25-022309 · form4-08192025_040801.xml · derivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,899 Underlying: Common Stock · 2,813 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F3 · derivative.exercise_date: This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,813 | $48.58 | $136,655.54 |
DisclosureSEC source: 0001415889-25-022309 · form4-08192025_040801.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.24 to $49.11 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:30 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,813 | $25.69 | $72,265.97 |
DisclosureSEC source: 0001415889-25-022309 · form4-08192025_040801.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 883 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-25-013661 · form4-05192025_050501.xml · derivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,712 Underlying: Common Stock · 883 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F4 · derivative.exercise_date: This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 883 | $46.02 | $40,635.66 |
DisclosureSEC source: 0001415889-25-013661 · form4-05192025_050501.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.19 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 883 | $25.69 | $22,684.27 |
DisclosureSEC source: 0001415889-25-013661 · form4-05192025_050501.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,929 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-25-013661 · form4-05192025_050501.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,595 Underlying: Common Stock · 1,929 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F4 · derivative.exercise_date: This option was granted on February 14, 2024 and vests over four years, with 25% of the shares underlying the option vested on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,929 | $46.18 | $89,081.22 |
DisclosureSEC source: 0001415889-25-013661 · form4-05192025_050501.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $46.00 to $46.61 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,929 | $25.69 | $49,556.01 |
DisclosureSEC source: 0001415889-25-013661 · form4-05192025_050501.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,395 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-25-008141 · form4-03142025_050301.xml · derivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,395 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,126 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-25-008141 · form4-03142025_050301.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,126 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,395 | $53.23 | $127,485.85 |
DisclosureSEC source: 0001415889-25-008141 · form4-03142025_050301.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to 53.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,395 | $33.02 | $79,082.90 |
DisclosureSEC source: 0001415889-25-008141 · form4-03142025_050301.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 13,126 | $53.31 | $699,747.06 |
DisclosureSEC source: 0001415889-25-008141 · form4-03142025_050301.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.00 to 53.71 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 13,126 | $33.02 | $433,420.52 |
DisclosureSEC source: 0001415889-25-008141 · form4-03142025_050301.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,719 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 16 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,395 Underlying: Common Stock · 1,719 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,662 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · derivative · entry 15 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,126 Underlying: Common Stock · 5,662 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,719 | $53.01 | $91,124.19 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $37.30 to $38.20 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,719 | $33.02 | $56,761.38 |
DisclosureSEC source: 0001415889-25-007856 · form4-03122025_050301.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 5, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.